Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer
| 适应症 | Lung Carcinoma |
|---|---|
| 分期 | 不适用 |
| 申办方 | M.D. Anderson Cancer Center |
| 状态 | 进行中（已停止招募） |
| 受试者人数 | 135 人 |
| 干预（药物） | Nicotine Replacement |
| 开始日期 | 2022年3月7日 |
| 完成日期 | 2025年10月17日 |
| 结果公布日 | 2026年8月5日 |
摘要
This clinical trial investigates the effects of switching from smoking regular cigarettes to electronic cigarettes (e-cigarettes) among older adult smokers at high risk for lung cancer. E-cigarettes use heated vapor to deliver nicotine. Information gained from this trial may help inform regulators of the potential risks and benefits of switching smokers at high risk for lung cancer to electronic cigarettes. This research also may help inform the Food and Drug Administration (FDA) how best to regulate e-cigarettes with the goal of improving public health.
Combustible Cigarettes Per Day
| Electronic Cigarettes Arm | 15.36 ± 8.93 cigarettes per day |
|---|---|
| Electronic Cigarettes Arm | 7.52 ± 7.54 cigarettes per day |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients W — National Cancer Institute (NCI)
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therap — National Cancer Institute (NCI)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
- Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)